Author: VernonEmeks May 29, 2020 at 06:08:24 from 22.214.171.124 in reply to: unnebulous foxiest posted by zpolet417 on August 26, 2016 at 03:25:42
Kohler report for The New York Times has found that the majority of Americans support paying more for prescription drugs. But, of course, those who feel strongly about it will not pay the full price of the pharmaceutical industry's profits.
The biggest reason is that more money is no longer enough to pay for generic drugs. This is because the pharmaceutical industry, led by two of its largest shareholders, drugmakers Pfizer and Merck, are spending tens of billions of dollars each year to persuade the federal government to add generic drugs to their list of prescription medicines. This is in addition to billions more being funneled through the Medicare payment system to insurers, doctors, hospitals and hospitals, to buy generic drugs.
As recently as the mid-1990s, in the aftermath of the Vietnam War, the United States spent almost half a billion dollars a year fighting drugs. But the pharmaceutical industry, through the drug manufacturers, made about 30% of that total. It had saved billions in health care costs, yet the drugmakers were not providing us with all the drugs they were promised. Now, under President Donald Trump, America is likely to make about 90% of the billions of dollars promised by the industry. And the real money, which is in a huge bubble created by pharmaceutical companies, has been lost.
This is a sad fact which will change the face of health care in the coming decades. America's drug firms will be able to make as much money as ever buying and selling the drugs they know we will need.
More and more Americans want their drug packages covered by Medicare, although they may not realize this because of the way our political leaders and the pharmaceutical industry cover up the true costs of prescription drugs.
The bottom line is this: Pharma and the drug companies are still spending billions in profits, but many of them are not getting the benefits they are trying to give us and because of this, the majority of Americans do not realize just how much the pharmaceutical industry is spending.
Americans need to demand that more money be paid into Medicare to cover the full cost of health care. In addition, some states should be free to adopt federal standards regarding the way pharmaceutical companies lobby the government.
These standards should be based on the American Medical Association, a group of the nation's leading physicians with the most influence over medical decisions. The AMA does not give drugs the kind of profits it has been allowed to have under President Ronald Reagan's health care reform law. A recent report from the American Academy of Neurology found that prescription drugs, like cancer drugs, have been a huge source of unnecessary and deadly disease throughout this century.
And the only way the American people will ever know about this is if and when a major national health care reform bill is introduced. President Trum
More renewable fuel companies seek asx listing
Wind and solar energy producers are starting to look for a way to raise the value of their renewable fuel assets.
They have filed an application to increase their listing at the Securities and Exchange Commission. The Securities and Exchange Commission (SEC) approved Wind and solar energy producers (SEOs)' requests for an asx listing on the Nasdaq Stock Market earlier this year. In early April, the U.S. Fish and Wildlife Service (USFWS) updated its guidelines for managing renewable fuel.
In the proposed listing, WES has sought to raise as much as $30 million to pay for research and development and the costs of producing renewable fuel. WES plans to seek up to $13.3 million in capital raising or financing through a financing facility owned by the company.
"The S&P/ASX/INVX Composite will not reflect, among other things, the costs associated with developing and marketing renewable fuel that is priced to drive fuel economy improvements through lower fuel prices, reduced CO2 emissions, and reduced dependence on fossil fuels," said the company in a statement regarding the approval.
The proposed listing, which would be for a 30-second spot on the Nasdaq's under-the-radar platform, is expected to become effective upon registration, and if approved, would be the first of it's kind in the United States.
This article was originally published by CoinDesk.
The leader in blockchain news, CoinDesk is a media outlet that strives for the highest journalistic standards and abides by a strict set of editorial policies. CoinDesk is an independent operating subsidiary of Digital Currency Group, which invests in cryptocurrencies and blockchain startups.
Note: Follow-ups should only be used for information of interest to all viewers. For other inquiries or personal communication please send an email if possible or use other contact information provided.
When you return to the board you will need to do a REFRESH or RELOAD to see your followup.